Back to Newsroom

Pharnext Confirms its Continuous Support of the Hereditary Neuropathy Foundation to Increase Global Awareness of Charcot-Marie-Tooth Disease

Paris, September 15, 2016 – Pharnext (ISIN FR00111911287), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, today confirmed its continuous support of the Hereditary Neuropathy Foundation (HNF) at the occasion of the Charcot-Marie-Tooth (CMT) disease awareness month.

Click here to read the full release